UPADACITINIB (Rinvoq) prior authorization at Humana
Submission criteria, P2P prep, and appeal path if denied — for prescribers and PA staff
Humana requires Janus Kinase Inhibitor prior-authorization documentation for UPADACITINIB (Rinvoq): a diagnosis with ICD-10 code, documented step-therapy history, and prescriber attestation of medical necessity. Standard PA decisions return in 30 days; if denied, prescribers and members have 60 days to appeal.
The PA criteria you'll need to meet
Humana reviews UPADACITINIB (Rinvoq) prior authorizations against its medical policy for Janus Kinase Inhibitor. Humana-specific context: Heavily Medicare Advantage focused. MA-specific appeal track (42 CFR Part 422 Subpart M) applies — 60 days to request reconsideration, NOT the 180 days for commercial plans. Auto-forward to IRE (Maximus) if Humana misses deadline.
Documentation packet checklist
- Chart note with diagnosis (ICD-10 code) and clinical severity markers
- Documented failure of, contraindication to, or intolerance of step-therapy alternatives in Janus Kinase Inhibitor
- Prior treatment history including dosing, duration, and reason for discontinuation
- Relevant labs, imaging, or assessment scores supporting medical necessity
- Prescriber attestation linking the FDA-approved indication to the patient's presentation
- Humana's medical policy URL referenced in the cover letter
Humana's common denial patterns
Pre-empting these patterns in the initial submission cuts rework and shortens time-to-approval:
- MA plan step therapy on Part B drugs
- Skilled nursing facility days
- Prior auth on specialty drugs
- OON emergency reduction
UPADACITINIB (Rinvoq)-specific denial patterns and context
Across payers (not just Humana), UPADACITINIB (Rinvoq)draws a distinct set of denial reasons rooted in the drug's label, REMS, and competitive landscape:
- TNF-inhibitor failure documentation required (post-2021 JAK class warning)
- Indication restriction (RA vs PsA vs UC vs Crohn's vs AD vs AS vs nr-axSpA)
- Dose restriction (15mg vs 30mg vs 45mg)
- Specialty pharmacy network restriction
Brand: Rinvoq. Selective JAK1 inhibitor. Approved for RA, PsA, AS, nr-axSpA, atopic dermatitis, ulcerative colitis, Crohn's disease, and giant cell arteritis (April 2025). Subject to JAK-class boxed warning.
Manufacturer patient-assistance program: AbbVie Complete — relevant when a Humana denial sticks and the patient needs bridge access while appealing.
If the PA is denied
Humana gives prescribers and members 60 days to file an internal appeal. Standard appeal decisions return within 30 days. Submit through the provider portal (https://www.humana.com/provider) with the same packet plus a peer-reviewed citation supporting UPADACITINIB (Rinvoq)for the patient's indication.
Medicare Advantage path: if Humana misses the appeal deadline the case auto-forwards to the Independent Review Entity (Maximus). Time-to-decision favors clinicians who request expedited review with a 72-hour clock when the delay risks harm.
Humana as a Medicare Advantage organization operates under 42 CFR Part 422 Subpart D for organization determinations: a standard (non-urgent) pre-service decision is due within 7 calendar days under CMS-0057-F (effective January 1, 2026; reduced from the prior 14-day standard), an expedited decision within 72 hours, and Part B drug decisions within 72 hours under the 2023 step-therapy rule extension. Missed deadlines auto-forward to the Independent Review Entity (Maximus Federal Services) without member action — track the calendar carefully because this is the most reliable lever in MA appeals.
Helping a patient appeal the denial directly? See the consumer guide: How to appeal a Humana denial on DenialHelp.
Contact Humana
- Provider portal: https://www.humana.com/provider
Frequently asked questions
What documentation does Humana need for UPADACITINIB (Rinvoq) prior auth?
Humana's typical PA packet for UPADACITINIB (Rinvoq): (1) chart note documenting the indication and prior-treatment failures, (2) supporting lab/imaging where indicated, (3) prescriber attestation that step-therapy alternatives were tried or contraindicated, (4) FDA-approved indication mapped to ICD-10 diagnosis. For Janus Kinase Inhibitor, expect clinical-criteria documentation specific to this class.
What's the turnaround time at Humana?
Standard UPADACITINIB (Rinvoq) PA decisions at Humana: 30 days. Urgent / expedited (member's life or function at risk): 72 hours under 45 CFR §147.136. Medicare Advantage adds the 14-day extension rule under 42 CFR Part 422.
What does Humana most often reject UPADACITINIB (Rinvoq) for?
Across Humana's book the common rejection patterns include: MA plan step therapy on Part B drugs; Skilled nursing facility days; Prior auth on specialty drugs. For UPADACITINIB (Rinvoq) specifically, expect step-therapy challenges and indication-restriction reviews when the use is at the edge of the FDA label or off-label.
How do I prep for a peer-to-peer with Humana on UPADACITINIB (Rinvoq)?
Lead with the FDA-approved indication and the specific clinical criteria the policy lists. Have the patient's chart open, document number, and policy URL on screen. State your name and credentials, the policy number, the indication, and the documented failures of step-therapy alternatives. Keep notes — if the P2P reviewer overturns, get the decision in writing.
Related PA criteria
Generate the UPADACITINIB (Rinvoq) PA packet
Open ApprovalHelp — generate a UPADACITINIB (Rinvoq) prior-auth packet tailored to Humana's criteria, with prescriber attestation and step-therapy documentation pre-filled.
Get started →Contact: hello@approvalhelp.com